Literature DB >> 35296921

Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.

Hongpan Zhang1,2, Meihan Liu2, Guobo Du1,2, Bin Yu3, Xiaojie Ma1,2, Yan Gui1,2, Lu Cao1,2, Xianfu Li4,5, Bangxian Tan6,7.   

Abstract

BACKGROUND: Non-small cell lung cancer is the most common subtype of lung cancer in the world. However, the survival rate of non-small cell lung cancer patients remains low currently. Immune checkpoint and long non-coding RNAs are emerging as critical roles in prognostic significance and the immunotherapeutic response of non-small cell lung cancer. It is critical to discern LncRNAs related with immune checkpoints in patients with Non-small cell lung cancer.
METHODS: In this study, immune checkpoint-linked LncRNAs were determined and achieved by the co-expression analysis. Immune checkpoint-linked LncRNAs with noteworthy prognostic value (P < 0.05) gained were next utilized to separate into two cluster by non-negative matrix factorization (NMF). Univariate and a least absolute shrinkage and selection operator were applied to construct an immune checkpoint-linked LncRNAs model. Kaplan-Meier analysis, Gene Set Enrichment Analysis, and the nomogram were utilized to investigate the LncRNAs model. Lastly, the capability immunotherapy and chemotherapy prediction value of this risk model were also estimated.
RESULTS: The model consisting of ten immune checkpoint-related LncRNAs was acknowledged to be a self-determining predictor of prognosis. Through regrouping the NSCLC patients by this model, difference between them more efficiently on immunotherapeutic response, tumor microenvironment and chemotherapy response could be discovered. This risk model related to the immune checkpoint-based LncRNAs may have an excellent clinical prediction for prognosis and the immunotherapeutic response in patients with NSCLC.
CONCLUSIONS: We performed an integrative analysis of LncRNAs linked with immune checkpoints and emphasized the significance of NSCLC subtypes classification, immune checkpoints related LncRNAs in estimating the tumor microenvironment score, immune cell infiltration of the tumor, immunotherapy, and chemotherapy response.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Immune checkpoint; Immunotherapeutic response; LncRNA; Non-small cell lung cancer; TME

Mesh:

Substances:

Year:  2022        PMID: 35296921     DOI: 10.1007/s00432-022-03940-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  48 in total

Review 1.  Gene regulation in the immune system by long noncoding RNAs.

Authors:  Y Grace Chen; Ansuman T Satpathy; Howard Y Chang
Journal:  Nat Immunol       Date:  2017-08-22       Impact factor: 25.606

2.  Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis.

Authors:  Pamela R de Santiago; Alejandro Blanco; Fernanda Morales; Katherine Marcelain; Olivier Harismendy; Marcela Sjöberg Herrera; Ricardo Armisén
Journal:  Life Sci       Date:  2020-12-29       Impact factor: 5.037

3.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 4.  Immunobiology of Long Noncoding RNAs.

Authors:  Maninjay K Atianand; Daniel R Caffrey; Katherine A Fitzgerald
Journal:  Annu Rev Immunol       Date:  2017-01-11       Impact factor: 28.527

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 7.  Development of immune checkpoint therapy for cancer.

Authors:  Jill M Fritz; Michael J Lenardo
Journal:  J Exp Med       Date:  2019-05-08       Impact factor: 14.307

8.  Large-scale public data reuse to model immunotherapy response and resistance.

Authors:  Jingxin Fu; Karen Li; Wubing Zhang; Changxin Wan; Jing Zhang; Peng Jiang; X Shirley Liu
Journal:  Genome Med       Date:  2020-02-26       Impact factor: 11.117

9.  Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.

Authors:  Dawei Chen; Hari Menon; Vivek Verma; Chunxiao Guo; Rishab Ramapriyan; Hampartsoum Barsoumian; Ahmed Younes; Yun Hu; Mark Wasley; Maria Angelica Cortez; James Welsh
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

10.  Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Authors:  Muhammad Zubair Afzal; Rima R Mercado; Keisuke Shirai
Journal:  J Immunother Cancer       Date:  2018-07-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.